0QQJ Stock Chart & Stats
CHF2.21
-CHF0.13(-5.88%)
At close: 4:00 PM EDT
CHF2.21
-CHF0.13(-5.88%)
Day’s Range― - ―
52-Week RangeCHF0.75 - CHF2.73
Previous CloseN/A
Volume4.00
Average Volume (3M)1.74K
Market Cap
CHF15.80M
Enterprise ValueCHF0.23
Total Cash (Recent Filing)CHF5.61M
Total Debt (Recent Filing)CHF0.00
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding7,230,626
10 Day Avg. Volume1,715
30 Day Avg. Volume1,742
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.5
Revenue Forecast (FY)CHF60.90M
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe absence of reported debt reduces interest-bearing obligations and gives Evolva greater financial flexibility than a highly levered company. This can help preserve resources for restructuring, product development, or commercialization while lowering balance-sheet strain over the next several quarters.
Reduced Cash BurnAlthough cash generation remains negative, the materially narrower burn rate indicates some improvement in resource consumption relative to earlier years. If sustained, this could extend financial runway and provide more time for management to rebuild operations or monetize remaining capabilities.
Biotechnology And Ingredient PlatformEvolva’s specialty-ingredient focus and biotechnology platform provide a differentiated basis for developing nutrition, health, and wellness products. Fermentation expertise and potentially licensable intellectual property can support scalable commercialization if the company re-establishes operating activity.
Bears Say
Zero Operating RevenueThe disappearance of revenue indicates that Evolva currently lacks operating scale and a demonstrated commercial base. Without recurring sales, the company has limited internal funding for research, commercialization, and overhead, making a durable recovery dependent on rebuilding products or licensing activity.
Persistent Negative Cash FlowPersistent negative operating and free cash flow shows that the business has not been self-funding across the reported period. Continued cash consumption can constrain investment, increase reliance on financing or asset reductions, and weaken the company’s ability to sustain operations through a prolonged recovery.
Shrinking Capital Base And Unstable ProfitabilityA declining equity and asset base, combined with sharply unstable returns, points to erosion of financial capacity and weak earnings durability. The brief 2024 profit did not establish a stable trend, while renewed losses can further reduce resources available for future growth.
Evolva Holding News
0QQJ FAQ
What was Evolva Holding’s price range in the past 12 months?
Evolva Holding lowest share price was CHF0.75 and its highest was CHF2.73 in the past 12 months.
What is Evolva Holding’s market cap?
Evolva Holding’s market cap is CHF15.80M.
When is Evolva Holding’s upcoming earnings report date?
Evolva Holding’s upcoming earnings report date is Feb 19, 2027 which is in 146 days.
How were Evolva Holding’s earnings last quarter?
Evolva Holding released its earnings results on Apr 29, 2026. The company reported -CHF0.04 earnings per share for the quarter.
Is Evolva Holding overvalued?
According to Wall Street analysts Evolva Holding’s price is currently Overvalued.
Does Evolva Holding pay dividends?
Evolva Holding does not currently pay dividends.
What is Evolva Holding’s EPS estimate?
Evolva Holding’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evolva Holding have?
Evolva Holding has 7,230,626 shares outstanding.
What happened to Evolva Holding’s price movement after its last earnings report?
Evolva Holding reported an EPS of -CHF0.04 in its last earnings report. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of Evolva Holding?
Currently, no hedge funds are holding shares in GB:0QQJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evolva Holding
EvoNext Holdings SA is dedicated to the exploration, creation, and distribution of pioneering ingredients across the nutritional, health, and wellness domains. Founded in 2004, the company's inception is attributed to Alexandra Santana Sørensen, Søren V. S. Nielsen, and Neil Goldsmith. Its corporate headquarters are located in Reinach, Switzerland.
Technical Analysis
Molecular Partners AG
―
Lonza Group Ltd
―
Bachem Holding AG
―
Kuros Biosciences
―
Xlife Sciences Ltd.
―